Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2017

Open Access 01-12-2017 | Research

5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin

Authors: Kaja Lund, Cathrine Elisabeth Olsen, Judith Jing Wen Wong, Petter Angell Olsen, Nina Therese Solberg, Anders Høgset, Stefan Krauss, Pål Kristian Selbo

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Login to get access

Abstract

Background

Development of resistance to 5-fluorouracil (5-FU) is a major problem in treatment of various cancers including pancreatic cancer. In this study, we reveal important resistance mechanisms and photochemical strategies to overcome 5-FU resistance in pancreatic adenocarcinoma.

Methods

5-FU resistant (5-FUR), epithelial-to-mesenchymal-like sub-clones of the wild type pancreatic cancer cell line Panc03.27 were previously generated in our lab. We investigated the cytotoxic effect of the endosomal/lysosomal-localizing photosensitizer TPCS2a (fimaporfin) combined with light (photochemical treatment, PCT) using MTS viability assay, and used fluorescence microscopy to show localization of TPCS2a and to investigate the effect of photodamage of lysosomes. Flow cytometric analysis was performed to investigate uptake of photosensitizer and to assess intracellular ROS levels. Expression and localization of LAMP1 was assessed using RT-qPCR, western blotting, and structured illumination microscopy. MTS viability assay was used to assess the effect of combinations of 5-FU, chloroquine (CQ), and photochemical treatment. Expression of CD105 was investigated using RT-qPCR, western blotting, flow cytometry, and fluorescence microscopy, and co-localization of TPCS2a and anti-CD105-saporin was assessed using microscopy. Lastly, the MTS assay was used to investigate cytotoxic effects of photochemical internalization (PCI) of the anti-CD105-immunotoxin.

Results

The 5-FUR cell lines display hypersensitivity to PCT, which was linked to increased uptake of TPCS2a, altered lysosomal distribution, lysosomal photodamage and increased expression of the lysosomal marker LAMP-1 in the 5-FUR cells. We show that inhibition of autophagy induced by either chloroquine or lysosomal photodamage increases the sensitivity to 5-FU in the resistant cells. The three 5-FUR sub-clones overexpress Endoglin (CD105). Treatment with the immunotoxin anti-CD105-saporin alone significantly reduced the viability of the CD105-expressing 5-FUR cells, whereas little effect was seen in the CD105-negative non-resistant parental cancer cell lines. Strikingly, using the intracellular drug delivery method photochemical internalization (PCI) by combining light-controlled activation of the TPCS2a with nanomolar levels of CD105-saporin resulted in strong cytotoxic effects in the 5-FUR cell population.

Conclusion

Our findings suggested that autophagy is an important resistance mechanism against the chemotherapeutic drug 5-FU in pancreatic cancer cells, and that inhibition of the autophagy process, either by CQ or lysosomal photodamage, can contribute to increased sensitivity to 5-FU. For the first time, we demonstrate the promise of PCI-based targeting of CD105 in site-specific elimination of 5-FU resistant pancreatic cancer cells in vitro. In conclusion, PCI-based targeting of CD105 may represent a potent anticancer strategy and should be further evaluated in pre-clinical models.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lund K, Dembinski JL, Solberg N, Urbanucci A, Mills IG, Krauss S. Slug-dependent Upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. PLoS One. 2015;10:e012368. Lund K, Dembinski JL, Solberg N, Urbanucci A, Mills IG, Krauss S. Slug-dependent Upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. PLoS One. 2015;10:e012368.
2.
go back to reference Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61:250–81.CrossRefPubMedPubMedCentral Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61:250–81.CrossRefPubMedPubMedCentral
3.
go back to reference Selbo PK, Weyergang A, Hogset A, Norum OJ, Berstad MB, Vikdal M, Berg K. Photochemical internalization provides time- and space-controlled endolysosomal escape of therapeutic molecules. J Control Release. 2010;148:2–12.CrossRefPubMed Selbo PK, Weyergang A, Hogset A, Norum OJ, Berstad MB, Vikdal M, Berg K. Photochemical internalization provides time- and space-controlled endolysosomal escape of therapeutic molecules. J Control Release. 2010;148:2–12.CrossRefPubMed
4.
go back to reference Berg K, Dietze A, Kaalhus O, Hogset A. Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin. Clin Cancer Res. 2005;11:8476–85.CrossRefPubMed Berg K, Dietze A, Kaalhus O, Hogset A. Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin. Clin Cancer Res. 2005;11:8476–85.CrossRefPubMed
5.
go back to reference Selbo PK, Sivam G, Fodstad O, Sandvig K, Berg K. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy. Int J Cancer. 2001;92:761–6.CrossRefPubMed Selbo PK, Sivam G, Fodstad O, Sandvig K, Berg K. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy. Int J Cancer. 2001;92:761–6.CrossRefPubMed
6.
go back to reference Berg K, Nordstrand S, Selbo PK, Diem TTT, Angell-Petersen E, Hogset A. Disulfonated tetraphenyl chlorin (TPCS2a), a novel photosensitizer developed for clinical utilization of photochemical internalization. Photochemical & Photobiological Sciences. 2011;10:1637–51.CrossRef Berg K, Nordstrand S, Selbo PK, Diem TTT, Angell-Petersen E, Hogset A. Disulfonated tetraphenyl chlorin (TPCS2a), a novel photosensitizer developed for clinical utilization of photochemical internalization. Photochemical & Photobiological Sciences. 2011;10:1637–51.CrossRef
7.
go back to reference Sultan AA, Jerjes W, Berg K, Hogset A, Mosse CA, Hamoudi R, Hamdoon Z, Simeon C, Carnell D, Forster M, et al. Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial. Lancet Oncol. 2016;17:1217–29.CrossRefPubMed Sultan AA, Jerjes W, Berg K, Hogset A, Mosse CA, Hamoudi R, Hamdoon Z, Simeon C, Carnell D, Forster M, et al. Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial. Lancet Oncol. 2016;17:1217–29.CrossRefPubMed
8.
9.
go back to reference Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, Jones L, Wyld P, Gillams A, Hatfield AWR. Photodynamic therapy for cancer of the pancreas. Gut. 2002;50:549–57.CrossRefPubMedPubMedCentral Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, Jones L, Wyld P, Gillams A, Hatfield AWR. Photodynamic therapy for cancer of the pancreas. Gut. 2002;50:549–57.CrossRefPubMedPubMedCentral
10.
go back to reference Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, Kent E, Bown SG, Hasan T, Pogue BW, et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110:1698–704.CrossRefPubMedPubMedCentral Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, Kent E, Bown SG, Hasan T, Pogue BW, et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110:1698–704.CrossRefPubMedPubMedCentral
11.
go back to reference Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth-factor-Beta receptor system in human endothelial-cells. J Biol Chem. 1992;267:19027–30.PubMed Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth-factor-Beta receptor system in human endothelial-cells. J Biol Chem. 1992;267:19027–30.PubMed
12.
go back to reference Wong SH, Hamel L, Chevalier S, Philip A. Endoglin expression on human microvascular endothelial cells - association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem. 2000;267:5550–60.CrossRefPubMed Wong SH, Hamel L, Chevalier S, Philip A. Endoglin expression on human microvascular endothelial cells - association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem. 2000;267:5550–60.CrossRefPubMed
13.
14.
go back to reference Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, et al. A phase I first-in-human study of TRC105 (anti-Endoglin antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18:4820–9.CrossRefPubMedPubMedCentral Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, et al. A phase I first-in-human study of TRC105 (anti-Endoglin antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18:4820–9.CrossRefPubMedPubMedCentral
15.
go back to reference Choueiri T, Agarwal N, Ho T, Pal SK, Seon B, Jivani M, Adams B, Shazer R, Theuer C. TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC). Ann Oncol. 2016;27:851TiP. Choueiri T, Agarwal N, Ho T, Pal SK, Seon B, Jivani M, Adams B, Shazer R, Theuer C. TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC). Ann Oncol. 2016;27:851TiP.
16.
go back to reference Choueiri T, Michaelson MD, Posadas E, Sonpavde G, McDermott D, Seon B, Jivani M, Shazer R, Adams B, Theuer C. A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol. 2016;27:804P.CrossRef Choueiri T, Michaelson MD, Posadas E, Sonpavde G, McDermott D, Seon B, Jivani M, Shazer R, Adams B, Theuer C. A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol. 2016;27:804P.CrossRef
17.
go back to reference Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, YK Y, Merino MJ, et al. A phase II clinical trial of TRC105 (anti-Endoglin antibody) in adults with advanced/metastatic Urothelial carcinoma. Clin Genitourin Cancer. 2017;15:77–85.CrossRefPubMed Apolo AB, Karzai FH, Trepel JB, Alarcon S, Lee S, Lee MJ, Tomita Y, Cao L, YK Y, Merino MJ, et al. A phase II clinical trial of TRC105 (anti-Endoglin antibody) in adults with advanced/metastatic Urothelial carcinoma. Clin Genitourin Cancer. 2017;15:77–85.CrossRefPubMed
18.
go back to reference Fujiwara K, Ohuchida K, Ohtsuka T, Mizumoto K, Shindo K, Ikenaga N, Cui L, Takahata S, Aishima S, Tanaka M. Migratory activity of CD105(+) pancreatic cancer cells is strongly enhanced by pancreatic Stellate cells. Pancreas. 2013;42:1283–90.CrossRefPubMed Fujiwara K, Ohuchida K, Ohtsuka T, Mizumoto K, Shindo K, Ikenaga N, Cui L, Takahata S, Aishima S, Tanaka M. Migratory activity of CD105(+) pancreatic cancer cells is strongly enhanced by pancreatic Stellate cells. Pancreas. 2013;42:1283–90.CrossRefPubMed
19.
go back to reference Wang XL, Liu YJ, Zhou KX, Zhang G, Wang FF, Ren JW. Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line. Int J Clin Exp Pathol. 2015;8:5105–12.PubMedPubMedCentral Wang XL, Liu YJ, Zhou KX, Zhang G, Wang FF, Ren JW. Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line. Int J Clin Exp Pathol. 2015;8:5105–12.PubMedPubMedCentral
20.
go back to reference Bostad M, Olsen CE, Peng Q, Berg K, Hogset A, Selbo PK. Light-controlled endosomal escape of the novel CD133-targeting immunotoxin AC133-saporin by photochemical internalization - a minimally invasive cancer stem cell-targeting strategy. J Control Release. 2015;206:37–48.CrossRefPubMed Bostad M, Olsen CE, Peng Q, Berg K, Hogset A, Selbo PK. Light-controlled endosomal escape of the novel CD133-targeting immunotoxin AC133-saporin by photochemical internalization - a minimally invasive cancer stem cell-targeting strategy. J Control Release. 2015;206:37–48.CrossRefPubMed
21.
go back to reference Selbo PK, Weyergang A, Bonsted A, Bown SG, Berg K. Photochemical internalization of therapeutic macromolecular agents: a novel strategy to kill multidrug-resistant cancer cells. J Pharmacol Exp Ther. 2006;319:604–12.CrossRefPubMed Selbo PK, Weyergang A, Bonsted A, Bown SG, Berg K. Photochemical internalization of therapeutic macromolecular agents: a novel strategy to kill multidrug-resistant cancer cells. J Pharmacol Exp Ther. 2006;319:604–12.CrossRefPubMed
22.
go back to reference Bostad M, Berg K, Hogset A, Skarpen E, Stenmark H, Selbo PK. Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties. J Control Release. 2013;168:317–26.CrossRefPubMed Bostad M, Berg K, Hogset A, Skarpen E, Stenmark H, Selbo PK. Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties. J Control Release. 2013;168:317–26.CrossRefPubMed
23.
go back to reference Teiten MH, Bezdetnaya L, Merlin JL, Bour-Dill C, Pauly ME, Dicato M, Guillemin F. Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells. Journal of Photochemistry and Photobiology B-Biology. 2001;62:146–52.CrossRef Teiten MH, Bezdetnaya L, Merlin JL, Bour-Dill C, Pauly ME, Dicato M, Guillemin F. Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells. Journal of Photochemistry and Photobiology B-Biology. 2001;62:146–52.CrossRef
24.
go back to reference Fu Y, Yang G, Zhu F, Peng C, Li W, Li H, Kim HG, Bode AM, Dong Z, Dong Z. Antioxidants decrease the apoptotic effect of 5-fu in colon cancer by regulating Src-dependent caspase-7 phosphorylation. Cell Death Dis. 2014;5 Fu Y, Yang G, Zhu F, Peng C, Li W, Li H, Kim HG, Bode AM, Dong Z, Dong Z. Antioxidants decrease the apoptotic effect of 5-fu in colon cancer by regulating Src-dependent caspase-7 phosphorylation. Cell Death Dis. 2014;5
26.
go back to reference Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.CrossRefPubMed Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.CrossRefPubMed
27.
go back to reference Jiang F, Robin AM, Katakowski M, Tong L, Espiritu M, Singh G, Chopp M. Photodynamic therapy with photofrin in combination with Buthionine Sulfoximine (BSO) of human glioma in the nude rat. Lasers Med Sci. 2003;18:128–33.CrossRefPubMed Jiang F, Robin AM, Katakowski M, Tong L, Espiritu M, Singh G, Chopp M. Photodynamic therapy with photofrin in combination with Buthionine Sulfoximine (BSO) of human glioma in the nude rat. Lasers Med Sci. 2003;18:128–33.CrossRefPubMed
28.
go back to reference Fukuda M. Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking. J Biol Chem. 1991;266:21327–30.PubMed Fukuda M. Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking. J Biol Chem. 1991;266:21327–30.PubMed
29.
go back to reference Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol. 2003;13:137–45.CrossRefPubMed Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol. 2003;13:137–45.CrossRefPubMed
31.
go back to reference Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 2005;12:1509–18.CrossRefPubMed Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 2005;12:1509–18.CrossRefPubMed
32.
go back to reference Liang X, Tang JC, Liang YL, Jin RA, Cai XJ. Suppression of autophagy by chloroquine sensitizes 5-fluorouracil-mediated cell death in gallbladder carcinoma cells. In: cell and. Bioscience. 2014;4 Liang X, Tang JC, Liang YL, Jin RA, Cai XJ. Suppression of autophagy by chloroquine sensitizes 5-fluorouracil-mediated cell death in gallbladder carcinoma cells. In: cell and. Bioscience. 2014;4
33.
go back to reference Yao CW, Kang KA, Piao MJ, Ryu YS, Fernando PM, MC O, Park JE, Shilnikova K, Na SY, Jeong SU, et al. Reduced Autophagy in 5-fluorouracil resistant colon cancer cells. Biomol Ther (Seoul). 2016;25:315–20.CrossRef Yao CW, Kang KA, Piao MJ, Ryu YS, Fernando PM, MC O, Park JE, Shilnikova K, Na SY, Jeong SU, et al. Reduced Autophagy in 5-fluorouracil resistant colon cancer cells. Biomol Ther (Seoul). 2016;25:315–20.CrossRef
34.
go back to reference Kung CP, Budina A, Balaburski G, Bergenstock MK, Murphy ME. Autophagy in tumor suppression and cancer therapy. Crit Rev Eukaryot Gene Expr. 2011;21:71–100.CrossRefPubMedPubMedCentral Kung CP, Budina A, Balaburski G, Bergenstock MK, Murphy ME. Autophagy in tumor suppression and cancer therapy. Crit Rev Eukaryot Gene Expr. 2011;21:71–100.CrossRefPubMedPubMedCentral
35.
go back to reference Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci. 2004;117:2805–12.CrossRefPubMed Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci. 2004;117:2805–12.CrossRefPubMed
36.
37.
go back to reference Trigueros-Motos L, Perez-Torras S, Casado FJ, Molina-Arcas M, Pastor-Anglada M. Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs. BMC Cancer. 2012;12:434.CrossRefPubMed Trigueros-Motos L, Perez-Torras S, Casado FJ, Molina-Arcas M, Pastor-Anglada M. Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs. BMC Cancer. 2012;12:434.CrossRefPubMed
38.
go back to reference Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 2007;178:437–51.CrossRefPubMedPubMedCentral Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 2007;178:437–51.CrossRefPubMedPubMedCentral
39.
go back to reference Lubeseder-Martellato C, Alexandrow K, Hidalgo-Sastre A, Heid I, Boos SL, Briel T, Schmid RM, Siveke JT. Oncogenic KRas-induced increase in fluid-phase Endocytosis is dependent on N-WASP and is required for the formation of pancreatic Preneoplastic lesions. Ebiomedicine. 2017;15:90–9.CrossRefPubMed Lubeseder-Martellato C, Alexandrow K, Hidalgo-Sastre A, Heid I, Boos SL, Briel T, Schmid RM, Siveke JT. Oncogenic KRas-induced increase in fluid-phase Endocytosis is dependent on N-WASP and is required for the formation of pancreatic Preneoplastic lesions. Ebiomedicine. 2017;15:90–9.CrossRefPubMed
40.
go back to reference Jin J, Huang M, Wei HL, Liu GT. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). World J Gastroenterol. 2002;8:1029–34.CrossRefPubMedPubMedCentral Jin J, Huang M, Wei HL, Liu GT. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). World J Gastroenterol. 2002;8:1029–34.CrossRefPubMedPubMedCentral
41.
go back to reference Zhitomirsky B, Assaraf YG. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget. 2015;6:1143–56.CrossRefPubMed Zhitomirsky B, Assaraf YG. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget. 2015;6:1143–56.CrossRefPubMed
42.
go back to reference Pan XH, Zhang XL, Sun HL, Zhang JJ, Yan MM, Zhang HB. Autophagy inhibition promotes 5-Fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. PLoS One. 2013;8 Pan XH, Zhang XL, Sun HL, Zhang JJ, Yan MM, Zhang HB. Autophagy inhibition promotes 5-Fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. PLoS One. 2013;8
43.
go back to reference Mercado-Pimentel ME, Hubbard AD, Runyan RB. Endoglin and Alk5 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev Biol. 2007;304:420–32.CrossRefPubMed Mercado-Pimentel ME, Hubbard AD, Runyan RB. Endoglin and Alk5 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev Biol. 2007;304:420–32.CrossRefPubMed
44.
go back to reference Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M, et al. Epithelial-Mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to Mesenchymal stem cells. Stem Cells. 2010;28:1435–45.CrossRefPubMedPubMedCentral Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M, et al. Epithelial-Mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to Mesenchymal stem cells. Stem Cells. 2010;28:1435–45.CrossRefPubMedPubMedCentral
45.
go back to reference Nomura Y, Yamashita T, Oishi N, Nio K, Hayashi T, Yoshida M, Hayashi T, Hashiba T, Asahina Y, Okada H, et al. De novo emergence of Mesenchymal stem-like CD105+ cancer cells by Cytotoxic agents in human Hepatocellular carcinoma. Transl Oncol. 2017;10:184–9.CrossRefPubMedPubMedCentral Nomura Y, Yamashita T, Oishi N, Nio K, Hayashi T, Yoshida M, Hayashi T, Hashiba T, Asahina Y, Okada H, et al. De novo emergence of Mesenchymal stem-like CD105+ cancer cells by Cytotoxic agents in human Hepatocellular carcinoma. Transl Oncol. 2017;10:184–9.CrossRefPubMedPubMedCentral
Metadata
Title
5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin
Authors
Kaja Lund
Cathrine Elisabeth Olsen
Judith Jing Wen Wong
Petter Angell Olsen
Nina Therese Solberg
Anders Høgset
Stefan Krauss
Pål Kristian Selbo
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-017-0662-6

Other articles of this Issue 1/2017

Journal of Experimental & Clinical Cancer Research 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine